New research indicates that newly developed anemia may significantly increase the risk of cancer diagnosis and all-cause mortality within 18 months, according to a study published in BMJ Journals.
Anemia, a prevalent blood disorder, has been identified as a potential major risk factor for cancer development. A recent study from Sweden aimed to determine whether newly developed anemia serves as an early warning sign for cancer or increased mortality from any cause. The findings were published in BMJ Journals and analyzed registry data from over 380,000 Swedish adults, half of whom had newly developed anemia, while the other half were matched by age and gender but did not have the condition. All participants were over 18 years old and cancer-free at the study’s outset.
The results revealed that individuals with incident anemia—new cases identified over a specified period—exhibited a significantly higher likelihood of receiving a cancer diagnosis, particularly within the first three months. Specifically, 6.2% of men and 2.8% of women with newly developed anemia were diagnosed with cancer during this timeframe.
Moreover, those with anemia faced a considerably elevated risk of death during the 18-month follow-up period. The study also found that specific types of anemia were linked to disease progression and mortality rates. Microcytic anemia, characterized by smaller-than-normal red blood cells, was more frequently associated with cancer, especially cancers affecting the digestive system and blood. In contrast, macrocytic anemia, where red blood cells are larger than normal, showed a stronger correlation with overall mortality rather than cancer specifically.
The researchers concluded that new-onset anemia is a “strong and sustained risk marker” for both the incidence of cancer and all-cause mortality. Elinor Nemlander, the lead author of the study and a researcher at the Department of Neurobiology, Care Sciences and Society at the Karolinska Institutet, commented on the findings in a press release from the Swedish medical university. She noted, “We found that both the risk of cancer and the risk of death are highest during the first months after anemia is detected, but that the increased risk persists later during follow-up as well.” Nemlander emphasized that these findings suggest anemia may indicate an underlying disease rather than being a condition in its own right.
In an interview with Fox News Digital, Nemlander highlighted that measurements such as red blood cell size are already “routinely available” in primary care settings. She pointed out that the study underscores the potential for utilizing existing data to identify early risks. “At the same time, the elevated risks persist over time, underscoring the need for structured follow-up and clear plans for continued evaluation, even when cancer is not initially identified,” she added.
It is important to note that the study was observational, indicating an association rather than establishing a direct causal relationship between anemia and cancer or death. Additionally, the research did not account for all causes of anemia, including factors such as alcohol use, malnutrition, chronic liver disease, inflammatory conditions, and gynecological blood loss. Nemlander also mentioned that some results might be influenced by who undergoes testing, underlying illnesses, and variations in how anemia is assessed across different healthcare settings.
As the medical community continues to explore the implications of these findings, the study serves as a reminder of the importance of monitoring blood health and the potential risks associated with newly developed anemia. The insights gained from this research may lead to improved early detection strategies and better patient outcomes in the future, according to BMJ Journals.